Topotecan-based Therapy
Topotecan-Based Therapy is a chemotherapeutic regimen classified under systemic cancer treatment that specifically incorporates the topoisomerase I inhibitor topotecan as the primary cytotoxic agent for targeting malignant cells in bone sarcoma.
832
Publications
46.6K
Citations
4.8K
Authors
1.3K
Institutions
Publications per year
2017–2026
112
832
1–5 of 832
4.8K
St. Jude Children's Research Hospital, United States
30 publications · 1.9K citations
24
h-index
The University of Texas at San Antonio Health Science Center, United States
18 publications · 1.4K citations
16
h-index
15
h-index
14
h-index
14
h-index
1–5 of 4.8K
1.3K
The University of Texas MD Anderson Cancer Center
Houston, United States
29 h-index
292 publications
18.9K citations

St. Jude Children's Research Hospital
Memphis, United States
29 h-index
191 publications
12.7K citations
Memorial Sloan Kettering Cancer Center
New York, United States
26 h-index
135 publications
10.1K citations
Gynecologic Oncology Group
Crofton, United States
19 h-index
46 publications
7.3K citations
National Cancer Institute
Bethesda, United States
19 h-index
155 publications
17.3K citations
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
16 h-index
66 publications
2.5K citations
Duke Medical Center
Durham, United States
16 h-index
29 publications
2.1K citations

Roswell Park Comprehensive Cancer Center
Buffalo, United States
15 h-index
27 publications
1.6K citations
1–8 of 1.3K
92 publications · 13.4K citations
59
h-index
Repository · 82 publications · 5.1K citations
39
h-index
58 publications · 2.3K citations
29
h-index
27 publications · 1.7K citations
21
h-index
24 publications · 974 citations
20
h-index
1–5